iBio Inc. – Building an End-to-End AI-powered Platform for Tomorrow’s Antibodies
Back
As an emerging biotech company, we leverage artificial intelligence as a cornerstone of our drug discovery platform. Our technology utilizes machine learning to explore high-value protein regions previously deemed inaccessible. This approach allows for the modeling of specific protein regions into small, engineered epitopes. These epitopes guide antibodies to precise areas of difficult-to-target proteins, triggering desired biological responses.
Our antibody optimization integrates machine learning with mammalian display technology. This fusion not only shortens the optimization timeline to under four weeks—compared to the traditional 4-8 months—but also enhances antibody developability, crucial for large-scale clinical and commercial manufacturing.
Moreover, we employ machine learning in our masking technology to develop conditionally activated antibodies. These antibodies distinguish between diseased and healthy tissue, aiming to improve safety and minimize side effects. This capability accelerates the identification and engineering of sophisticated antibodies, potentially leading to safer treatments that can block disease spread and stimulate an immune response.
We’ve created an organizational model in which all disciplines have expertise in artificial intelligence. This enables us to break down the conventional barriers between data scientists and biologists, fostering a team fluent in both disciplines. This integrated expertise streamlines our drug discovery and development process, enhancing efficiency and eliminating redundancy. While artificial intelligence doesn’t solve every challenge in drug discovery, it empowers us to explore novel targets and makes our operations more agile and innovative.
Submitted by iBio Inc.